Article Sidebar
Views PDF: 1772
ANALYZE THE CHARACTERISTICS OF USING SGLT-2 INHIBITORS IN INPATIENTS WITH HEART FAILURE AT THE CARDIOVASCULAR INSTITUTE – 108 MILITARY CENTRAL HOSPITAL
Main Article Content
Abstract
Objective: Investigate the appropriateness of indication and dosing regimen of SGLT2-inhibitors in hospitalized patients at the Cardiovascular Institute – 108 Military Central Hospital. Subject and method: A descriptive, retrospective study based on electronic medical records of inpatients prescribed SGLT-2 inhibitors at the Cardiovascular Institute – 108 Military Central Hospital from 01/2022 to 06/2022. Evaluate the appropriateness of indication and dosage based on recommendations in guideline of AHA 2022, ESC 2021 and Ministry of Health 2022 and drug label at our hospital. Results and conclusion: During hospital stay, SGLT2 inhibitors, including empagliflozin and dapagfiflozin, are indicated early for heart failure. The proportions of HfrEF, HfmrEF and HppEF were 41.4%, 25.2% and 20.5%, respectively. Inappropriate indications due to contraindication in patients with eGFR equal to or below 20 ml/min/1.73 m2 were recorded in 13.6% with empagliflozin and 3.7% with dapagliflozin. Adherence rate to dosage recommendations was 100% in our study.
Article Details
References
2. McMurray, J.J., et al., A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European journal of heart failure, 2019. 21(5): p. 665-675.
3. McDonagh, T.A., et al., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021. 42(36): p.3599-3726.
4. Heidenreich, P.A., et al., 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022. 145(18): p. e895-e1032.
5. Visseren, F.L.J., et al., 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal, 2021.42(34):p.3227-3337.
6. Salah, H.M., et al., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2022. 21(1): p. 20.
7. McMurray, J.J.V., et al., Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019. 381(21): p. 1995-2008.
8. Packer, M., et al., Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020. 383(15): p. 1413-1424.
9. Anker, S.D., et al., Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021. 385(16): p. 1451-1461.
10. Meraz-Muñoz, A.Y., J. Weinstein, and R. Wald, eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360, 2021. 2(6): p. 1042-1047.